ライフサイエンスコーパス: gatifloxacin

1 90.4% (clindamycin) to 100% (vancomycin and gatifloxacin).

2 cal and clinical effectiveness compared with gatifloxacin.

3 in high-level resistance to moxifloxacin and gatifloxacin.

4 (34%) to moxifloxacin, and 3 of 13 (23%) to gatifloxacin.

5 ized to 1 of 4 antibiotics (azithromycin 1%, gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%) an

6 yes were injected intravitreally with 0.1 mL gatifloxacin (0.3%), vancomycin (1.0%), either antibioti

7 hout stratification to 7 days of either oral gatifloxacin (10 mg/kg per day) or intravenous ceftriaxo

8 tention-to-treat population (120 assigned to gatifloxacin, 119 to ceftriaxone).

9 oxacin, 50 microM; moxifloxacin, 129 microM; gatifloxacin, 130 microM; levofloxacin, 915 microM; and

10 tivally prior to or coapplied topically with gatifloxacin 16 hours after infection.

11 Patients received gatifloxacin 400 mg either by the intravenous or NG rout

12 was compared with a 4-month regimen in which gatifloxacin (400 mg per day) was substituted for ethamb

13 The gatifloxacin 5-microg disk test produced zone diameters

14 .5%; oxacillin, 54.7%; ciprofloxacin, 51.0%; gatifloxacin, 51.0%; and moxifloxacin, 47.0%.

15 ted the efficacy of long-term treatment with gatifloxacin, a bactericidal antibiotic known to be effe

16 riteria and quality control were studied for gatifloxacin, a new 8-methoxy fluoroquinolone, tested ag

17 Ciprofloxacin and gatifloxacin also inhibited hOAT3.

18 Control quinolones (ciprofloxacin and gatifloxacin) also performed at a similarly high level o

19 the United States) were also tested against gatifloxacin and 12 other antimicrobial agents.

20 historic BI/NAP1 isolates were resistant to gatifloxacin and moxifloxacin (P<0.001).

21 High-level resistance (MIC, >32 mug/ml) to gatifloxacin and moxifloxacin was documented for 46.7% o

22 Resistance to gatifloxacin and moxifloxacin was more common in current

23 , including 15 (39.5%) isolates resistant to gatifloxacin and moxifloxacin, members of the C-8-methox

24 serve as an ophthalmic delivery vehicle for gatifloxacin and to evaluate its in vitro and in vivo de

25 ials were the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which

26 Gatifloxacin appears to be a potent anti-Haemophilus flu

27 y released fluoroquinolones moxifloxacin and gatifloxacin are reviewed in terms of their clinical pro

28 comitant gastric tube feeding did not affect gatifloxacin bioavailability (interrupted tube feeds: 98

29 is needed to identify those patients in whom gatifloxacin bioavailability is reduced and for whom an

30 ough concomitant tube feeding did not affect gatifloxacin bioavailability, critical illness resulted

31 ness and concomitant gastric tube feeding on gatifloxacin bioavailability.

32 [range 24.1 to 63.1] microg x h/mL, p =.60) gatifloxacin (bioavailability: 98.5% [range 61.1% to 119

33 Serial serum gatifloxacin concentrations (from 5 mins to 24 hrs) were

34 G) for >or=12 hrs were randomized to receive gatifloxacin concurrently with continuous tube feeding o

35 ssessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-se

36 Subjects received 400 mg of gatifloxacin daily during an initial 2-week course of th

37 educed and for whom an empirical increase in gatifloxacin dose should be considered.

38 , ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited concentration-dependent inhibitio

39 od culture, only two (3%) of 58 who received gatifloxacin failed treatment versus 15 (23%) of 65 who

40 lation, 16 (26%) of 62 patients who received gatifloxacin failed treatment, compared with four (7%) o

41 er fluoroquinolones, including levofloxacin, gatifloxacin, gemifloxacin, and garenoxacin (BMS 284756)

42 gorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipenem, levofloxacin, merope

43 The gatifloxacin (GFX) solubility-enhancing property of a si

44 y: moxifloxacin (MXF), levofloxacin (LVX) or gatifloxacin (GFX).

45 ermore, topical coapplication of MMP13i with gatifloxacin greatly improved disease outcomes, includin

46 istant isolates, the MICs for ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovaflox

47 events at two years were 23.7 percent in the gatifloxacin group and 25.1 percent in the placebo group

48 h high-level resistance to ciprofloxacin and gatifloxacin had emerged.

49 18 (15%) patients who received gatifloxacin had treatment failure, compared with 19 (16

50 Moxifloxacin and gatifloxacin have improved potency and are able to overc

51 arly intravitreal injection of vancomycin or gatifloxacin improved the therapeutic outcome of B. cere

52 variability that may complicate the role of gatifloxacin in sequential intravenous-to-oral therapy.

53 r enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance an

54 CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penici

55 Gatifloxacin (MIC at which 90% of the isolates are inhib

56 Gatifloxacin (MIC50, 0.008 microg/ml) was slightly more

57 for H. influenzae strains, corresponding to gatifloxacin MICs of 0.008 or 0.016 microg/ml.

58 Neither gatifloxacin nor vancomycin was toxic to retinal cells i

59 Moxifloxacin and gatifloxacin offer improved spectrum of activity, increa

60 Combining topical gatifloxacin or ofloxacin with intracameral agent was no

61 were resistant to ciprofloxacin (p = 0.001), gatifloxacin (p = 0.003), and ofloxacin (p = 0.002) comp

62 Compared with topical gatifloxacin, prophylaxis using topical aminoglycoside w

63 Only gatifloxacin reached aqueous concentrations greater than

64 fluoroquinolone-containing (moxifloxacin and gatifloxacin) regimens have failed to shorten duration o

65 t performed well, detecting 52 of 60 (86.7%) gatifloxacin-resistant isolates and 22 of 23 moxifloxaci

66 The gatifloxacin susceptibility breakpoint proposed for nonf

67 Gatifloxacin use was associated with the highest rate (R

68 trial with ceftriaxone, the fluoroquinolone gatifloxacin was associated with equivalent or better fe

69 ccumulation of other fluoroquinolones (e.g., gatifloxacin) was also slightly enhanced.

70 hat the strains resistant to levofloxacin or gatifloxacin were associated with higher colony counts t

71 eneration fluoroquinolones, moxifloxacin and gatifloxacin, were introduced in 2003 promising improved

72 Resistance to moxifloxacin and gatifloxacin when tested at 2 mug/mL was low in all coun

73 All trials compared gatifloxacin with 1 of the following comparator drugs: c

74 veness of early treatment with vancomycin or gatifloxacin, with or without dexamethasone, for experim

75 Eyes treated at 2 hours with vancomycin or gatifloxacin, with or without dexamethasone, maintained

76 e and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceft